Fig. 6

The anti-CD98hc-DM1 has antitumoral activity in vivo and potentiates the action of standard of care drugs. A Analysis of the “in vivo” effect of anti-CD98hc-DM1 on tumor growth in nude mice implanted with MDA-MB231 cells. Arrows indicate days of administration of anti-CD98hc-DM1. Data are plotted as mean tumor volumes ± SEM. P values were calculated using Student t test (two-sided). B Effect of CD98hc-DM1 on the weight of mice. Data are plotted as mean ± SD of six mice/group. C Analyses of DM1, pH3 and pH2AX levels in tumors from mice. Seventeen days after the last treatment, tumors were resected and immediately frozen in liquid nitrogen. Expression of DM1, pH3 and pH2AX was analyzed by Western. β-actin was used as a loading control. D Quantitation of the levels of DM1, pH3 and pH2AX of the experiment performed in (C). The graphs represent the mean ± S.D of the different proteins (arbitrary units) of control and treated (anti-CD98hc-DM1) groups. Student’s t test was used to analyze differences among groups. (E and F) MDA-MB231 cells were treated with CD98hc-DM1 alone or in combination with Docetaxel (E) or Vinorelbine (F) for four days at the indicated doses (nM)